The research compound in Mysimba®
Mysimba® is a weight management medicine from Currax Pharmaceuticals. Its active compound is Naltrexone/Bupropion — which is what this catalogue supplies, as a research material.
This is not Mysimba®, and NOVALYTE LABS has no affiliation with Currax Pharmaceuticals. We supply the compound Naltrexone/Bupropion for laboratory research only — not for human consumption, diagnostic, therapeutic or veterinary use. Mysimba® is a trademark of Currax Pharmaceuticals, referenced here only to identify the compound.
Mysimba is the European brand for the naltrexone and bupropion combination; the same combination is marketed as Contrave in the United States.
It is unusual in this category for acting on neither the incretin nor the amylin system: bupropion is a dopamine and noradrenaline reuptake inhibitor, naltrexone an opioid antagonist, and the combination is studied for its effect on hypothalamic appetite signalling.
The combination is supplied here as a research material, not as the branded medicine.
Naltrexone/Bupropion in this catalogue
100mg oral tablets
How Naltrexone/Bupropion is supplied here
Everything below describes the research material in this catalogue, not the medicine.
| Compound | Naltrexone/Bupropion |
|---|---|
| Presentation | 100mg oral tablets |
| Dosage options | 100mg |
| Research category | Metabolic Research |
| Batch COA | Certificate supplied with order |
| Availability | In stock |
| Intended use | Laboratory research only — not for human or veterinary use |
Common questions
What is the active compound in Mysimba?
Naltrexone/Bupropion. Mysimba is a registered trademark of Currax Pharmaceuticals, approved for weight management.
Is this Mysimba?
No. NOVALYTE LABS supplies Naltrexone/Bupropion as a research material with batch documentation. It is not Mysimba, it is not a medicine, it is not supplied for human use, and there is no affiliation with Currax Pharmaceuticals.
Why is Naltrexone/Bupropion sold under more than one brand?
Because a brand is tied to an approved indication rather than to the molecule. Naltrexone/Bupropion is marketed as Mysimba and also as Contrave — same compound, different approvals.
Other brands using Naltrexone/Bupropion
The same compound is marketed under more than one brand, usually because each brand carries a different approved indication.